Rinvoq (upadacitinib) / AbbVie - LARVOL DELTA

The role of JAKs signaling in SpA pathogenesis and its inhibition. (PubMed, Expert Rev Clin Immunol) - "JAKi are useful in the treatment of SpA and are recommended by international authorities in patients suffering from SpA. Despite the promising results, ongoing research is essential to assess the benefit-risk profile of JAKi in SpA."

Journal • Review • Ankylosing Spondylitis • Immunology • Inflammation • Seronegative Spondyloarthropathies • Spondylarthritis

A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease (clinicaltrials.gov) - P2 | N=107 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Trial completion • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

Maintenance and Deepening of Clinical Response in Adult Patients With Moderate-to-Severe Hidradenitis Suppurativa Receiving Upadacitinib: Post Hoc Analysis of a Phase 2 Study (EADV 2025) - No abstract available

Clinical • P2 data • Retrospective data • Dermatology • Hidradenitis Suppurativa • Immunology

TADPol study: a real-world evidence on dupilumab and upadacitinib in the treatment of moderate-to-severe atopic dermatitis in Poland. (EADV 2025) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Giant Cell Arteritis Refractory to Interleukin-6 and Interleukin-17 Inhibition Treated With Upadacitinib. (PubMed, ACR Open Rheumatol) - "We report a unique case of extracranial GCA refractory to glucocorticoids, azathioprine, tocilizumab (IL-6 inhibitor), and secukinumab (IL-17A inhibitor) that responded robustly to upadacitinib, a selective JAK1 inhibitor. To our knowledge, this is the first reported case of GCA demonstrating resistance to both IL-6 and IL-17 inhibition but clinical and imaging remission with JAK inhibition, highlighting the role of upadacitinib as a therapy for patients with GCA."

Journal • Giant Cell Arteritis • Immunology • Vasculitis • IL17A • IL6

Molecular Signatures in Inflammatory Skin Disease (clinicaltrials.gov) - P=N/A | N=300 | Recruiting | Sponsor: Prof. Dr. Stephan Weidinger | Trial completion date: Dec 2028 ➔ Dec 2029 | Trial primary completion date: Dec 2027 ➔ Dec 2028

Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Oncology • Psoriasis

Patients with Atopic Dermatitis Using Oral Contraceptive Pills or Hormone Replacement Therapy: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer) (EADV 2025) - No abstract available

Adverse events • Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Genetic Disorders • Immunology • Skin Cancer • Solid Tumor • Venous Thromboembolism

Efficacy and Safety of Upadacitinib and Vedolizumab Combination for Refractory Orofacial Granulomatosis Associated with Panenteric Crohn's Disease: A Case Report. (PubMed, Reports (MDPI)) - "Multiple therapies were attempted during her life, including systemic steroids and immunomodulator drugs as Thalidomide, Adalimumab, and Ustekinumab in combination with topical steroid injections and Cyclosporin application, with no or minimal benefit. Only Infliximab showed good efficacy, but it was suspended due to side effects... This is a unique case of orofacial granulomatosis associated with pan-enteric Crohn's disease successfully treated with Upadacitinib. More data are needed to explore its potential benefits in this clinical condition."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • JAK1

Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis. (PubMed, Clin Gastroenterol Hepatol) - "Tofacitinib and upadacitinib appear to have similar effectiveness and safety profiles when used for the treatment of ASUC."

HEOR • Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Upadacitinib demonstrates significant efficacy in giant cell arteritis: results from the SELECT-GCA study (PubMed, Z Rheumatol) - No abstract available

Journal • Giant Cell Arteritis • Immunology

Fatal Liver Failure After Herpes-Simplex-Virus-2-Induced Acute Necrotizing Hepatitis: A Case Report. (PubMed, Case Reports Hepatol) - "Empirical treatment with an antimicrobial regimen, intravenous aciclovir, acetylcysteine, and plasmapheresis (PPH) was initiated. This is only the second documented case of fulminant ALF due to HSV2 hepatitis in a patient undergoing JAK inhibition, and the first involving upadacitinib. It highlights the importance of considering primary herpesvirus infection as a potential cause of ALF, particularly in immunocompromised patients, and underscores the need for early antiviral intervention to improve outcomes."

Journal • Cardiovascular • CNS Disorders • Hematological Disorders • Hepatic Encephalopathy • Hepatology • Herpes Simplex • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Liver Failure • Mucositis • Rheumatoid Arthritis • Rheumatology • Septic Shock • Solid Organ Transplantation • Transplantation

Unilateral Osteonecrosis of the Femoral Head in a Patient with Atopic Dermatitis Due to Uncontrolled Topical Steroid Treatment, a Case Report. (PubMed, Reports (MDPI)) - "The patient reported the prolonged uncontrolled use of topical mometasone furoate for five years due to AD. Following the diagnosis, topical corticosteroids were discontinued, and the treatment was shifted to tacrolimus and, subsequently, to oral methotrexate with folic acid...It underscores the importance of monitoring systemic side effects in dermatological therapies and educating patients on proper corticosteroid use. Alternative treatments, such as upadacitinib, should be considered in young male patients to prevent severe complications."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Orthopedics • Pain

Upadacitinib Induced Facial Erythema and Edema in Atopic Dermatitis: A Paradoxical Adverse Event (EADV 2025) - No abstract available

Adverse events • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Network Meta-Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease. (PubMed, Aliment Pharmacol Ther) - "Novel IL-23 inhibitors (such as mirikizumab, risankizumab and guselkumab) and anti-TNFs (such as infliximab and adalimumab) ranked high in the induction of clinical and endoscopic remission. This highlights the potential of novel advanced therapies for CD."

Journal • Retrospective data • Review • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • IL23A

Effectiveness of Tralokinumab for Upadacitinib-Refractory Atopic Dermatitis: 48-week Retrospective Study. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Real-world Effectiveness by Body Regions and Safety of Upadacitinib in Canadian Adult Patients With Atopic Dermatitis who Were Inadequate Responders or Intolerant to Dupilumab: Results From the CAN UpTIMISE Study (EADV 2025) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Lipid and Hepatic Changes in Patients Treated with Upadacitinib: A 52-Week Follow-Up Study (EADV 2025) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology

Upadacitinib Versus Acitretin for the Resolution of Pustules in Palmoplantar Pustulosis During Acute Phase: A Single-Center, Open-Label Prospective Cohort Study. (PubMed, Am J Clin Dermatol) - P4 | "UPA demonstrated superior efficacy over ACI in rapidly clearing pustules and improving skin lesions and quality of life in acute PPP episodes. The findings suggest that JAK1 inhibition may be a promising therapeutic approach for PPP, warranting further investigation in larger trials."

Journal • Dermatology • Immunology • Inflammation • Psoriasis

Upadacitinib and its role in the vitiligo treatment: a potential therapeutic tool (EADV 2025) - No abstract available

Dermatology • Immunology • Vitiligo

Real-world effectiveness and safety of abrocitinib, baricitinib and upadacitinib in atopic dermatitis: A systematic review and meta-analysis (EADV 2025) - No abstract available

Real-world • Real-world effectiveness • Real-world evidence • Retrospective data • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Effectiveness and Safety of individual dosing alternatives of Upadacitinib in atopic dermatitis real-world population (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Real-world effectiveness and safety of upadacitinib for atopic dermatitis in adults and adolescents: a retrospective multicenter analysis of minimal disease activity criteria (EADV 2025) - No abstract available

Real-world • Real-world effectiveness • Real-world evidence • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Efficacy of Upadacitinib vs Dupilumab Treatment for Moderate to Severe Atopic Dermatitis: Analysis of Time Spent in Response State from the Level Up Study (EADV 2025) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Efficacy and safety of oral upadacitinib-topical ruxolitinib combination therapy in the treatment of progressive nonsegmental vitiligo. (PubMed, JAAD Int) - No abstract available

Journal • Dermatology • Immunology • Vitiligo

Real-world utilization and minimal disease activity achievement with upadacitinib in atopic dermatitis: interim analysis of the multicenter China P24-965 study (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology